Eli Lilly and Co (NYSE:LLY) insider Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $76.72 on Thursday. Eli Lilly and Co has a 52 week low of $75.71 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The company has a market cap of $85,874.41, a P/E ratio of -383.58, a PEG ratio of 1.43 and a beta of 0.23.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the prior year, the firm earned $0.95 earnings per share. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Beach Investment Management LLC. bought a new stake in shares of Eli Lilly and during the second quarter valued at approximately $400,000. 440 Investment Group LLC grew its stake in shares of Eli Lilly and by 1.3% during the second quarter. 440 Investment Group LLC now owns 7,782 shares of the company’s stock valued at $640,000 after purchasing an additional 100 shares during the last quarter. Abbrea Capital LLC boosted its stake in Eli Lilly and by 2.5% in the second quarter. Abbrea Capital LLC now owns 2,463 shares of the company’s stock valued at $203,000 after acquiring an additional 60 shares during the last quarter. Convergence Investment Partners LLC bought a new position in Eli Lilly and in the second quarter valued at approximately $483,000. Finally, United Asset Strategies Inc. bought a new position in Eli Lilly and in the second quarter valued at approximately $416,000. 76.45% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently issued reports on LLY. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Barclays increased their price target on shares of Eli Lilly and from $90.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $92.02.
COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Co (LLY) Insider Sells $72,981.00 in Stock” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/08/eli-lilly-and-co-lly-insider-sells-72981-00-in-stock.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.